Enrique Grande, ESMO 2022: Post-hoc analysis investigating PD-L1 expression on immune cells, and improved OS with atezolizumab in patients with urothelial cancer
PD-L1 assays use various methods to predict PD-L1/PD-1 blockade outcomes, recent data suggests clinically relevant PD-L1–expressing immune cells are dendritic cells. Dr Enrique Grande Pulido (MD Anderson Cancer Centre Madrid, Madrid, Spain) joins touchONCOLOGY to discuss a post-hoc analysis investigating PD-L1 expression on immune cells by SP142 co-localises with dendritic cells, and the associated improved overall survival with atezolizumab in patients with untreated metastatic urothelial cancer.
The abstract entitled ‘PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)‘ Abstract 1735O, was presented at European Society for Medical Oncology (ESMO) 2022.
- Could you give us a brief overview of PD-L1 assays to predict outcomes of PD-1/PD-L1 blockade, and their findings to date? (0:17)
- What did the IMvigor 130 trial teach us about the efficacy and safety of atezolizumab in patients with untreated metastatic urothelial cancer? (1:18)
- What were the aims and design of the post-hoc analysis you are presenting? (2:25)
- What were the findings of the analysis? (3:31)
- How can these findings be used to improve outcomes with PD-L1 inhibitors? (4:18)
Disclosures: Enrique Grande Pulido is a consultant for Advanced Accelerator Applications, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Dr. Reddy’s, Eisai, Esteve, Eusa Pharma, Genetracer, GSK, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, Tecnofarma, Thermo Fisher Scientific, and Zodiac; receives grant/research support from Astellas, Astra Zeneca, IPSEN, Lexicon, Merck KGaA, MTEM/Threshold/Tersera, Nanostring Technologies, Pfizer, and Roche; is on the advisory board for Roche; and receives honoraria/honorarium from Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Filmed in coverage of ESMO 2022
Share this Video
Related Videos In Genitourinary Cancer
Looking to the future with Arnulf Stenzl: What can we hope to see in urological oncology in the next 5 years?
Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, discusses what he hopes to see in the field of uro-oncological surgery in the next five years. He hopes this will include improving early detection of prostate cancer and therefore the possibility of avoiding surgery; improving prognostic factors and diagnosis in early disease […]
Arnulf Stenzl, EAU23: Latest developments in urological oncology
It was a pleasure to hear from the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the pivotal new projects and initiatives the society are currently working on. Topics covered Minimalise any uro-oncologic surgery, more precise, complete removal of tumour, improving outcomes (00:37) Developments in robot-assisted surgery […]
Arnulf Stenzl: Pivotal new projects of the European Association of Urology (EAU)
It was a pleasure to hear from the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the pivotal new projects and initiatives the society are currently working on. Topics covered Meetings and introducing more virtual, web-based education post-COVID (00:20) Projects, real-world data, future strategies (3:30) Development of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!